share_log

Reunion Neuroscience (TSE:REUN) Earns "Buy" Rating From HC Wainwright

Financial News Live ·  Jan 22, 2023 01:51

HC Wainwright restated their buy rating on shares of Reunion Neuroscience (TSE:REUN – Get Rating) in a research report report published on Thursday morning. The brokerage currently has a C$20.00 price target on the stock.

Separately, Roth Capital started coverage on Reunion Neuroscience in a research note on Friday, December 16th. They set a buy rating and a C$11.00 price target for the company.

Get Reunion Neuroscience alerts:

Reunion Neuroscience Stock Performance

Shares of REUN stock opened at C$1.77 on Thursday. Reunion Neuroscience has a fifty-two week low of C$1.08 and a fifty-two week high of C$13.10.

About Reunion Neuroscience

(Get Rating)

Field Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions.

Further Reading

  • MarketBeat Week in Review – 1/16 – 1/20
  • Does Old Dominion Show That Trucking Is Hitting The Brakes?
  • Nordstrom Puts Fear Of Markdowns Into Retail Sector
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth

Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment